WRBY:NYE-Warby Parker Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 19.51

Change

0.00 (0.00)%

Market Cap

USD 2.03B

Volume

2.53M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-09 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-3.34 (-1.42%)

USD 67.81B
ALC Alcon AG

-5.39 (-5.84%)

USD 46.04B
RMD ResMed Inc

-1.48 (-0.60%)

USD 35.86B
BAX Baxter International Inc

-0.39 (-1.14%)

USD 17.46B
AVTR Avantor Inc

-0.51 (-2.29%)

USD 15.18B
ATR AptarGroup Inc

-0.45 (-0.26%)

USD 11.72B
TFX Teleflex Incorporated

-2.44 (-1.23%)

USD 9.08B
BLCO Bausch + Lomb Corp

-0.91 (-4.45%)

USD 7.20B
STVN Stevanato Group SpA

-0.54 (-2.54%)

USD 5.19B
INFU InfuSystems Holdings Inc

+0.45 (+4.97%)

USD 0.17B

ETFs Containing WRBY

RETL Direxion Daily Retail Bul.. 0.00 % 1.09 %

-0.23 (-2.25%)

USD 0.05B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 38.37% 89% A- 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.37% 89% A- 86% B+
Trailing 12 Months  
Capital Gain 93.94% 89% A- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 93.94% 89% A- 91% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.27% 11% F 6% D-
Dividend Return -10.27% 11% F 5% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.77% 63% D 34% F
Risk Adjusted Return -33.38% 16% F 8% B-
Market Capitalization 2.03B 36% F 67% D+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector